Loading stock data…
Immuneering Corporation (IMRX)
$5.05+0.29 (+6.09%)
Market ClosedLast close Jun 29
Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Immuneering Corporation in the Healthcare sector is trading at $5.05 with a market capitalization of $308M. Wall Street consensus targets $17.00 (6 analysts), implying a +236.6% move over the next 12 months. The stock is currently 50% below its 52-week high of $10.08, remaining 12.0% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. Risk note: RSI 84 is overbought against a weak tape. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +236.6% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Overbought RSI 84 against a weak tape — risk of pullback
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$15.33M↓ | -$13.75M↑ | -$15.38M↓ | -$14.76M↑ | -$15.49M |
| Net Income | -$13.46M↓ | -$11.58M↑ | -$14.96M↓ | -$14.43M↑ | -$15.05M |
Peer Comparison
JNJUNHPFE
Fundamentals
Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$307.96M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.38
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-26.36%
Volume
Today's trading volume
1.92M
Recent News
IMRX Begins Dosing in Phase III Pancreatic Cancer Study, Stock Up
Immuneering stock rises after dosing the first patient in a pivotal phase III study of atebimetinib plus mGnP for first-line metastatic pancreatic cancer.
IMRX Stock On Track For Worst Day In Nearly 5 Months — What’s Driving The Selloff?
The stock gained 14% in the previous session but is now on track for its steepest one-day decline since early January, if losses hold.
We're Hopeful That Immuneering (NASDAQ:IMRX) Will Use Its Cash Wisely
There's no doubt that money can be made by owning shares of unprofitable businesses. By way of example, Immuneering...
Immuneering CEO Touts 64% 12-Month Survival in Pancreatic Cancer; Phase 3 Launch Nears
Immuneering (NASDAQ:IMRX) CEO Benjamin J. Zeskind told investors at a Needham conference session that 2026 has started with what he described as “extraordinary” early survival results for the company’s lead program, atebimetinib, in first-line pancreatic cancer, and outlined multiple upcoming clinic
X4 Pharmaceuticals, Immuneering and Tango Therapeutics Are Getting New Analyst Attention
Analyst sentiment across three small-cap biotechs has turned notably positive, with fresh coverage initiations and maintained Buy-equivalent ratings from institutional research desks ahead of 2026 clinical catalysts. All three names carry verified Buy or Overweight ratings, and the gap between current trading prices and analyst targets ranges from substantial to dramatic. Three Calls, Three Catalysts ... X4 Pharmaceuticals, Immuneering and Tango Therapeutics Are Getting New Analyst Attention